Edinburgh Research Explorer

11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1385-1393
Number of pages9
JournalDrugs
Volume73
Issue number13
DOIs
Publication statusPublished - Sep 2013

Abstract

Inhibition of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) has been proposed as a novel therapeutic target for the treatment of type 2 diabetes mellitus. Over 170 new compounds targeting 11β-HSD1 have been developed. This article reviews the current published literature on compounds that have reached phase II clinical trials in patients with type 2 diabetes, and summarises the preclinical evidence that such agents may be useful for associated conditions, including peripheral vascular disease, coronary artery disease and cognitive decline. In clinical trials, 11β-HSD1 inhibitors have been well tolerated and have improved glycaemic control, lipid profile and blood pressure, and induced modest weight loss. The magnitude of the effects are small relative to other agents, so that further development of 11β-HSD1 inhibitors for the primary therapeutic indication of type 2 diabetes has stalled. Ongoing programmes are focused on additional benefits for cognitive function and other cardiovascular risk factors.

    Research areas

  • 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1, SPLANCHNIC CORTISOL PRODUCTION, HEPATIC INSULIN SENSITIVITY, IMPROVES COGNITIVE FUNCTION, METABOLIC SYNDROME, ADIPOSE-TISSUE, HUMAN OBESITY, GLUCOCORTICOID ACTION, SELECTIVE-INHIBITION, HYPERGLYCEMIC MICE

ID: 10768575